ADORA2A and autoimmune disease: As indicated above, increased expression of the A2aR on lymphocytes has been documented in patients with SLE, which suggests that targeting of the A2aR on T‐bet+ ABCs may be a viable approach to treat autoimmune diseases in patients [95].